

Figure S1. OncoPrint image of TCGA analysis performed in 7,084 patients and >7,251 samples, including information on the 12 studies included, mutation frequency, and mutation types.



Figure S2. Percentage gene amplification and deep deletion observed for *miR-490/3P* in the different studies. Data were analyzed was from TCGA that had 7,084 patients (7,251 samples) from 12 studies. Shown are analysis based on cancer-related studies.




Table SI. Clinicopathological characteristics of female breast cancer patients included in the present study.

Characteristics	DCIS (n=10)	IDC (n=35)
Age		
>60 years	7	24
≥60 years	3	11
Stage		
0/I	10	1
II	0	4
IIIA	0	5
IIIB	0	12
IV	0	13
N-stage		
N0	10	0
N1	0	1
N2	0	24
N3	0	10
Molecular subtype		
HER2 <sup>+</sup>	7	12
ER <sup>+</sup> PR <sup>+</sup> (Luminal A)	0	3
ER <sup>+</sup> PR <sup>-</sup> HER2 <sup>+</sup> (Luminal B)	2	9
ER <sup>-</sup> PR <sup>-</sup> HER2 <sup>-</sup> (triple-negative)	1	11
Surgery		
No surgery	8	0
Breast-conserving surgery	2	3
Mastectomy	0	32
Chemotherapy/radiation		
Yes	10/1	35/29
No	0/0	0/0

The race of all the patients was Asian. HER2, human epidermal growth factor receptor 2; ER, estrogen receptor; PR, progesterone receptor.